Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

OSPREY: PSMA-targeted PET/CT imaging in prostate cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.20
Views: 167

Dr Frédéric Pouliot - Centre Hospitalier Universitaire (CHU) de Quebec

Dr Frédéric Pouliot speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the OSPREY study.

OSPREY is a PII/II study of PSMA-targeted PET/CT imaging in prostate cancer patients.

Dr Pouliot outlines the exciting results, and some more details of the study design.

He explains when these tracers may be in the clinic, the effectiveness, and also at what point of diagnosis they should be used.

Related videos

follow us

Biosimilar Medicines Core Principles and Communication

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation